News : dermatology

View:
 

Found press releases

 

MOBERG DERMA AND MENARINI GROUP SIGN AGREEMENT FOR EMTRIX IN ITALY

12/9/2011 2:00 AM EST  -   MOBERG DERMA AB
Moberg Derma AB (STO: MOB) has entered into a distribution agreement with Menarini Group for Emtrix® – for discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis. Under the agreement Menarini’s OTC Division is granted exclusive rights to market and sell Emtrix® in Italy under the trademark YouDerm Emtrix®.
“The agreement is part of our international commercialization of Emtrix®. As...

MOBERG DERMA AND MEDA EXTEND LICENSE AGREEMENT

11/30/2011 8:00 AM EST  -   MOBERG DERMA AB
Moberg Derma AB (publ.) and Meda have entered into an additional license agreement for Nalox™ - Moberg Derma’s patented product for the treatment of discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis. The agreement extends Meda's rights to market and sell Nalox™ to Russia, Turkey and several countries in Eastern Europe. Moberg Derma assumes production and supply responsibility.

November Facial Aesthetics Masterclass with Dr. Koenraad de Boulle

10/28/2011 10:10 AM EST  -   Cosmetic Courses
Places selling out fast for exclusive event with world-renowned dermatologist
Cosmetic Courses are proud to have Dr. Koenraad de Boulle presenting their Masterclass in Facial Aesthetics on 19th November 2011, 9am-5pm, at St Anne’s College in Oxford.

Dr. De Boulle is an expert dermatologist and director of the private Aalst Dermatology Clinic in Belgium. He is highly respected within the Dermatology and...

MOBERG DERMA AND MEDA SIGN AGREEMENT FOR NALOX IN EUROPE

9/19/2011 2:00 AM EST  -   MOBERG DERMA AB
Moberg Derma AB (OMX: MOB) and Meda AB have entered into a license agreement covering rights for Nalox® - Moberg Derma’s patented product for the treatment of discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis. Under the agreement, Meda is granted exclusive rights to market and sell Nalox® in a large number of countries in Europe. Moberg Derma assumes production and supply...

MOBERG DERMA SIGNS DISTRIBUTION AGREEMENT IN AUSTRALIA AND NEW ZEELAND

6/8/2011 2:00 AM EST  -   MOBERG DERMA AB
Moberg Derma AB (publ.) has entered into a distribution agreement with OzHealth Pharma for Emtrix® – for discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis. Under the agreement OZ Pharma Health is granted exclusive rights to market and sell Emtrix® in Australia and New Zeeland.
”The agreement is part of our international commercialization of Emtrix®, which now will be marketed...

MOBERG DERMA REPORTS POSITIVE CLINICAL RESULTS FOR EMTRIX

2/2/2011 4:45 AM EST  -   MOBERG DERMA AB
Moberg Derma AB today reports positive results from a clinical trial of Emtrix. The trial included 75 patients with nail fungus (onychomycosis) and the results showed that 92% of the patients improved after 8 weeks of treatment. Already after 2 weeks, 77% of the patients were improved.
The open clinical trial was conducted at two clinical centers in Sweden during the second half of 2010. The purpose was to...

MOBERG DERMA SIGNS DISTRIBUTION AGREEMENT IN SWITZERLAND

12/3/2010 10:00 AM EST  -   MOBERG DERMA AB
Moberg Derma AB (publ.) has entered into a distribution agreement with Gebro Pharma AG S.A. for Emtrix® – for treatment of discolored and deformed nails resulting from fungal infection  (onychomycosis) or psoriasis, and Kaprolac® – for problems with dry and flaky skin and. Under the agreement, Gebro is granted exclusive rights to market and sell Emtrix®, Kaprolac® Dandruff Shampoo and Kaprolac® Scalp Solution in...

PUBLICATION OF SUPPLEMENT TO PROSPECTUS REGARDING OFFER TO SUBSCRIBE FOR SHARES ...

11/18/2010 6:10 AM EST  -   MOBERG DERMA AB
Today Moberg Derma AB (publ) (”Moberg Derma”) has published a supplement to the previously published prospectus regarding offer to subscribe for shares in Moberg Derma. The supplementary prospectus has been prepared due to that Moberg Derma on November 16, 2010 has been granted the permit to initiate a clinical phase II-trial for MOB-015 from the Swedish Medical Products Agency.

MOBERG DERMA IS GRANTED PERMIT TO INITIATE PHASE II-TRIAL FOR MOB-015

11/17/2010 2:00 AM EST  -   MOBERG DERMA AB
The Swedish Medical Products Agency has granted Moberg Derma permit to initiate a clinical phase II trial for MOB-015. MOB-015 is Moberg Dermas next generation topical treatment for nail fungus, with fungicidal, keratolytic and emollient properties.
Nail fungus (onychomycosis) chiefly manifests itself in thickening and discoloration of the nails. The disease is common, affecting about 100 million patients in...

MOBERG DERMA TO LIST ON NASDAQ OMX STOCKHOLM

11/15/2010 2:30 AM EST  -   MOBERG DERMA AB
The Board of Directors of Moberg Derma AB (publ) has applied for a listing of its shares on NASDAQ OMX Stockholm, the main list. In connection with the listing, Moberg Derma will broaden the ownership through a new issue of SEK 140m.

· The offer comprises a new issue of SEK 140 million corresponding to 3,111,112 – 3,783,784 shares as well as an over-allotment option of up to SEK 21 million through a new...